The influence of medroxyprogesterone acetate (MPA) on hormone parameters in prostatic carcinoma patients
- PMID: 2968326
- DOI: 10.1007/BF02550662
The influence of medroxyprogesterone acetate (MPA) on hormone parameters in prostatic carcinoma patients
Abstract
In ten patients suffering from previously untreated, advanced, non-metastatic prostatic carcinoma, the effect of MPA on the hormonal parameters of testosterone and luteinizing hormone (LH) was examined. The dosage of MPA amounted to 500 mg i.m. daily for a week. Thereafter 1000 mg i.m. every four weeks were applied. Full castration could be achieved in all patients, and this effect could be kept up during the time of observation. The tolerance was good, there were no side effects.
Similar articles
-
[High-dosage medroxyprogesterone acetate treatment in advanced prostatic cancer].Wien Klin Wochenschr. 1987 Oct 9;99(19):682-6. Wien Klin Wochenschr. 1987. PMID: 2961131 German.
-
Hormonal effects of high dose medroxyprogesterone acetate treatment in males with renal or prostatic adenocarcinoma.Scand J Urol Nephrol. 1988;22(1):15-8. doi: 10.1080/00365599.1988.11690377. Scand J Urol Nephrol. 1988. PMID: 2968646
-
Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma.Urology. 1989 Mar;33(3):175-8. doi: 10.1016/0090-4295(89)90385-3. Urology. 1989. PMID: 2465644
-
An overview of clinical trials with high-dose medroxyprogesterone acetate (HD-MPA) in endocrine-related tumors other than breast cancer.Chemioterapia. 1986 Jun;5(3):164-72. Chemioterapia. 1986. PMID: 2941173 Review.
-
Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer.Cancer Chemother Pharmacol. 1994;35 Suppl:S97-100. doi: 10.1007/BF00686930. Cancer Chemother Pharmacol. 1994. PMID: 7994797 Review.
References
MeSH terms
Substances
LinkOut - more resources
Medical